#USA #Chicago #Bridge to Life #ILTS 2025 #organ preservation

Bridge to Life to Present at ILTS 2025

In a significant advancement for organ preservation and transplantation technology, Bridge to Life™, a leader in the field, has announced its participation in the upcoming International Liver Transplantation Society (ILTS) Congress 2025. Scheduled to take place in Singapore from May 28 to May 31, 2025, the company will present nine thought-provoking abstracts, including two late-breaking studies that underscore the importance of innovations in liver transplantation.

The abstracts being presented include key studies addressing hypothermic oxygenated perfusion (HOPE)—their effects on organ preservation and the potential life-saving impacts of this technology, especially among pediatric transplant recipients. This year's presentations are particularly crucial, as they are set to explore methods and findings that could reshape future practices in liver transplantation.

Highlighted Abstracts

1. Late Breaker: The impact of mechanical perfusion on ischemia-reperfusion injury in liver transplantation—an age-stratified donor analysis. This groundbreaking study will be presented by Marco Maria Pascale and collaborators from Policlinico Universitario Fondazione Agostino Gemelli, Italy.
2. Late Breaker: Mechanical perfusion in liver transplantation—Is this a turning point for mid-volume centers? The findings from this analysis will speak to the capabilities of diverse medical facilities to adopt leading-edge technologies.
3. Case Report: Utilizing the HOPE machine for transplants in unusual scenarios, crucial insights from the Birmingham Children’s Hospital and Queen Elizabeth Hospital teams in the UK will be highlighted.
4. Preliminary Results: HOPE in pediatric liver transplants, a collaborative effort involving leading scientists from Hospital Universitario La Paz in Spain, will showcase the initial outcomes from utilizing HOPE technology in young patients.
5. Recurrence Analysis: Evaluating HOPE in patients with hepatocellular carcinoma under transplantation—insights into recurrence following procedures using hypothermically perfused grafts.
6. Future Perspectives: The promising impacts of HOPE on liver transplantation for Acute-on-Chronic Liver Failure (ACLF) and Acute Liver Failure (ALF).
7. Implementation Results: Outcomes from implementing HOPE in human liver grafts before transplant operations at Hospital Universitario Rio Hortega in Spain.
8. Combined Transplant Strategies: The achievements and insights regarding combined heart and liver transplants with HOPE from the Hospital Universitari Vall d'Hebron in Barcelona.
9. Experience from a Single Center: A case study spotlighting the experience with desperate grafts and outcomes from a leading hospital in Barcelona, with shared learnings for the broader medical community.

Workshop and Symposium Engagement

In addition to presenting these significant findings, Bridge to Life will host a Hands-on Workshop on Liver Machine Perfusion on May 28, 2025, designed for deeper engagement and practical understanding of the presented technologies. This is an excellent opportunity for health professionals to gain hands-on experience with the advanced HOPE perfusion system.

Also, on May 29 at 3 PM SST (UTC+8), Bridge to Life will sponsor an insightful symposium titled "Pushing the Boundaries of Hypothermic Oxygenated Perfusion: Addressing Challenges and Opportunities in the Asia-Pacific Region." This forum will feature renowned speakers such as Dr. Sonal Asthana from Aster Hospitals, Dr. Andrea Schlegel from the Cleveland Clinic, and Dr. Rebeca Sanabria Mateos from Queen Elizabeth Hospital.

About Bridge to Life Ltd

Since its inception, Bridge to Life Ltd has been pioneering organ preservation solutions, focusing on high-quality products such as Belzer UW®, EasiSlush®, and the HOPE technology embodied in their VitaSmart™ system. The company is committed to prioritizing quality, innovation, and accessibility, ensuring collaboration with vital transplant centers and organ procurement organizations worldwide. The VitaSmart technology is CE marked and is available in various international markets, enhancing its appeal and application in the global healthcare landscape.

In conclusion, Bridge to Life’s involvement at ILTS 2025 represents a remarkable opportunity to elevate the discourse surrounding organ transplantation and preservation, promising advancements that could save countless lives.